Literature DB >> 35104884

COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection.

Idris Boudhabhay1, Alexandra Serris2, Aude Servais1, Delphine Planas3,4, Aurélie Hummel1, Bruno Guery1, Perrine Parize2, Claire Aguilar2, Myriam Dao1, Claire Rouzaud2, Elsa Ferriere1, Bertrand Knebelmann1, Hamza Sakhi5,6, Marianne Leruez7, Dominique Joly1, Olivier Schwartz3,4, Fanny Lanternier2, Timothée Bruel3,4.   

Abstract

BACKGROUND: Patients on maintenance haemodialysis (HD) have an increased risk of severe coronavirus disease 2019 (COVID-19) and a reduced response to vaccines. Data are needed to identify immune correlates of protection in this population.
METHODS: Following a COVID-19 outbreak among vaccinated patients in a HD unit, clinical data and serological response to BNT162b2 vaccine were retrospectively recorded.
RESULTS: Among 53 patients present in the dialysis room, 14 were infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) alpha variant (COVID_Pos) and 39 were not. Compared with uninfected patients, COVID_Pos patients more frequently had additional causes of immunosuppression (50% versus 21%; P = .046) and were more often scheduled on the Monday-Wednesday-Friday (MWF) shift (86% versus 39%; P = .002). Moreover, COVID_Pos had lower anti-spike (S) immunoglobulin G (IgG) titres than uninfected patients {median 24 BAU/mL [interquartile range (IQR) 3-1163] versus 435 [99-2555]; P = .001} and lower neutralization titres [median 108 (IQR 17-224) versus 2483 (481-43 908); P = .007]. Anti-S and neutralization antibody titres are correlated (r = 0.92, P < .001). In multivariable analysis, an MWF schedule {odds ratio [OR] 10.74 [95% confidence interval (CI) 1.9-93.5], P = .014} and anti-S IgG titres 1 month before the outbreak [<205 BAU/mL: OR 0.046 (95% CI 0.002-0.29), P = .006] were independently associated with COVID-19 infection. None of the patients with anti-S IgG >284 BAU/mL got infected. Ten of 14 COVID_Pos patients were treated with casirivimab and imdevimab. No patient developed severe disease.
CONCLUSIONS: Anti-S IgG titre measured prior to exposure correlates to protection from SARS-CoV-2 infection in HD patients. BNT162b2 vaccination alone or in combination with monoclonal antibodies prevented severe COVID-19.
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.

Entities:  

Keywords:  BNT162b2 mRNA vaccination; COVID-19 outbreak; haemodialysis; humoral response; monoclonal antibodies

Mesh:

Substances:

Year:  2022        PMID: 35104884      PMCID: PMC8903345          DOI: 10.1093/ndt/gfac016

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   7.186


  6 in total

1.  SARS-CoV-2 Infection during the Omicron Surge among Patients Receiving Dialysis: The Role of Circulating Receptor-Binding Domain Antibodies and Vaccine Doses.

Authors:  Maria E Montez-Rath; Pablo Garcia; Jialin Han; LinaCel Cadden; Patti Hunsader; Curt Morgan; Russell Kerschmann; Paul Beyer; Mary Dittrich; Geoffrey A Block; Julie Parsonnet; Glenn M Chertow; Shuchi Anand
Journal:  J Am Soc Nephrol       Date:  2022-08-16       Impact factor: 14.978

2.  Diminished Short- and Long-Term Antibody Response after SARS-CoV-2 Vaccination in Hemodialysis Patients.

Authors:  Louise Füessl; Tobias Lau; Isaac Lean; Sandra Hasmann; Bernhard Riedl; Florian M Arend; Johanna Sorodoc-Otto; Daniela Soreth-Rieke; Marcell Toepfer; Simon Rau; Haxhrije Salihi-Halimi; Michael Paal; Wilke Beuthien; Norbert Thaller; Yana Suttmann; Gero von Gersdorff; Ron Regenauer; Anke von Bergwelt-Baildon; Daniel Teupser; Mathias Bruegel; Michael Fischereder; Ulf Schönermarck
Journal:  Vaccines (Basel)       Date:  2022-04-13

3.  SARS-CoV-2 infection during the Omicron surge among patients receiving dialysis: the role of circulating receptor-binding domain antibodies and vaccine doses.

Authors:  Maria E Montez-Rath; Pablo Garcia; Jialin Han; LinaCel Cadden; Patti Hunsader; Curt Morgan; Russell Kerschmann; Paul Beyer; Mary Dittrich; Geoffrey A Block; Shuchi Anand; Julie Parsonnet; Glenn M Chertow
Journal:  medRxiv       Date:  2022-03-18

4.  Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study.

Authors:  Borja Quiroga; María José Soler; Alberto Ortiz; Carlos Jesús Jaravaca Mantecón; Nathasha Nava Pérez; Marta Serra Martín; Yurika Sato; Antonio José Marin Franco; Diana Flor Pazmiño Zambrano; Rafael Lucena Valverde; Mayra Ortega Diaz; Carmen Calderón González; Juan Manuel Cazorla López; Mónica Pereira; Emilio González Parra; Ana Sánchez Horrillo; Carmen Sánchez González; Néstor Toapanta; Secundino Cigarrán Guldris; Rosa Sánchez Hernández; Soledad Pizarro Sánchez; María Muñiz Rincón; Nuria Garcia-Fernández; Natalia Blanco Castro; Rocío Collantes Mateo; Manuel Augusto Quiroz Morales; Beatriz Escamilla-Cabrera; Isabel Berdud Godoy; Beatriz Gil-Casares Casanova; Alba Leyva; José Rojas; Ron T Gansevoort; Patricia de Sequera
Journal:  Clin Kidney J       Date:  2022-07-26

5.  SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines.

Authors:  Louise Füessl; Ulf Schönermarck
Journal:  Lancet Reg Health Eur       Date:  2022-09-13

6.  Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study.

Authors:  Paul Martin; Sarah Gleeson; Candice L Clarke; Tina Thomson; Helena Edwards; Katrina Spensley; Paige Mortimer; Stacey McIntyre; Alison Cox; Graham Pickard; Liz Lightstone; David Thomas; Stephen P McAdoo; Peter Kelleher; Maria Prendecki; Michelle Willicombe
Journal:  Lancet Reg Health Eur       Date:  2022-09-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.